Portable low-flow nasal oxygen versus ambient air in patients with chronic lung disease and exercise-induced hypoxaemia: a randomised controlled crossover non-inferiority trial.
Mona Lichtblau, Carmen Wick, Anna Titz et al.
✦ AI-curated · Sources linked
In 30 seconds
This pragmatic, randomised controlled crossover trial evaluated the effectiveness of portable low-flow supplemental oxygen therapy (SOT) versus ambient air in patients with chronic lung disease (CLD) experiencing exercise-induced hypoxaemia. The study involved 40 patients and found that the mean difference in 6-minute walk distance (6MWD) was 0 m, indicating non-inferiority of ambient air to SOT. However, SOT significantly reduced dyspnoea scores.
Key findings
- Mean difference in 6MWD between ambient air and SOT was 0 m (95% CI -14 to 13 m).
- SOT significantly lowered dyspnoea scores compared to ambient air.
- Patient preferences were nearly equal, with 49% preferring ambient air and 51% preferring SOT.
- A clinically meaningful improvement in 6MWD of >35 m was observed in five patients.
Why it matters
Understanding the effectiveness of supplemental oxygen therapy in improving exercise capacity and reducing dyspnoea is crucial for managing patients with chronic lung disease. This study provides insights into patient preferences and the need for effective oxygen delivery systems.